奥美拉唑联合瑞巴派特治疗慢性胃炎的有效性评估

Objective To explore the effectiveness of omeprazole combined with rebamipide regimen in the treatment of helicobacter pylori(Hp) negative chronic gastritis. Methods Ninety cases of Hp negative chronic gastritis patients were selected from our hospital from January 2023 to January 2024. The subjects were divided into two groups using the random number table method, each group of 45 cases. The control group patients used sodium omeprazole for injection, and the research group used rebaprazan tablets on the basis of the above drugs. Before and after treatment, the quality of life of the two groups was compared, and the clinical efficacy and drug reactions were compared. Results After treatment, the clinical efficacy of the research group was higher(P<0.05), the quality of life of the research group was higher than that of the control group(P<0.05), and there was no statistically significant difference in the comparison of the two groups of adverse reactions(P>0.05), the symptom score of the research group patients was lower than that of the control group(P<0.05). Conclusion Hp negative chronic gastritis patients with omeprazole combined with rebaprazan treatment can improve the clinical efficacy, and will not increase the risk of adverse reactions, thereby improving the quality of life of, reducing the clinical symptom score, and the effect is significant.